Prostate Cancer Reports
54

Volume 5 Issue 2
February 2017



Home > Prostate Cancer Reports > Volume 5, Year 2017 > Number 2, February


CONTENTS



CASE REPORTS
DIAGNOSIS AND EVALUATION
ETIOLOGY, PATHOGENESIS AND PATHOLOGY
INTEGRATIVE MEDICINE
OVERALL MANAGEMENT
PROGNOSIS AND OUTCOMES
TREATMENT





CASE REPORTS



Kawai H, Shiba H, Kanehira M, Sakamoto T, Furukawa K, Yanaga K.
Successful resection of a solitary metastatic liver tumor from prostate cancer 15 years after radical prostatectomy: a case report.
Surg Case Rep. 2017 Dec;3(1):17. doi: 10.1186/s40792-017-0292-4. Epub 2017 Jan 25.
Source | Abstract | Full text | Similar articles





DIAGNOSIS AND EVALUATION



Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, Rathkopf D, Loriot Y, de Bono J, Tombal B, Abhyankar S, Lin P, Krivoshik A, Phung D, Beer TM.
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.
Prostate Cancer Prostatic Dis. 2017 Jan 24. doi: 10.1038/pcan.2016.71. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Delahunt B, Grignon DJ, Samaratunga H, Srigley JR, Leite KR, Kristiansen G, Evans AJ, Kench JG, Egevad L.
Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System.
Comment on:Kryvenko ON et al, Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System [Arch Pathol Lab Med. 2016]
Arch Pathol Lab Med. 2017 Feb;141(2):182-183. doi: 10.5858/arpa.2016-0300-LE.
Source | Abstract | Full text | Similar articles




Egevad L, Delahunt B, Samaratunga H, Srigley JR.
Utility of Reporting the Percentage of High-grade Prostate Cancer.
Eur Urol. 2016 Apr;69(4):599-600. doi: 10.1016/j.eururo.2015.11.008. Epub 2015 Nov 19.
Comment on: Sauter G et al, Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. [Eur Urol. 2016]
Source | Abstract | Full text | Similar articles




Epstein JI, N. Kryvenko ON.
In Reply.
Comment on: Delahunt B et al, Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System [Arch Pathol Lab Med. 2017]
Arch Pathol Lab Med. 2017 Feb;141(2):pp. 183-184. doi: 10.5858/arpa.2016-0434-LE
Source | Abstract | Full text | Similar articles




Giesel FL, Kesch C, Yun M, Cardinale J, Haberkorn U, Kopka K, Kratochwil C, Hadaschik BA.
18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer.
Clin Genitourin Cancer. 2016 Dec 29. pii: S1558-7673(16)30375-5. doi: 10.1016/j.clgc.2016.12.029. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Lindenberg ML, Turkbey B, Mena E, Choyke PL.
Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review.
JAMA Oncol. 2017 Jan 12. doi: 10.1001/jamaoncol.2016.5840. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Mathieu R, Moschini M, Beyer B, Gust KM, Seisen T, Briganti A, Karakiewicz P, Seitz C, Salomon L, de la Taille A, Rouprêt M, Graefen M, Shariat SF.
Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study.
Prostate Cancer Prostatic Dis. 2017 Jan 10. doi: 10.1038/pcan.2016.66. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Parker WP, Evans JD, Stish BJ, Park SS, Olivier K, Choo R, Nathan MA, Welch BT, Karnes RJ, Mynderse LA, Pisansky TM, Kwon ED, Lowe VJ, Davis BJ.
Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography.
Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):526-535. doi: 10.1016/j.ijrobp.2016.11.014. Epub 2016 Nov 17.
Source | Abstract | Full text | Similar articles




Sauter G, Clauditz T, Steurer S, Wittmer C, Büscheck F, Krech T, Lutz F, Lennartz M, Harms L, Lawrenz L, Möller-Koop C, Simon R, Jacobsen F, Wilczak W, Minner S, Tsourlakis MC, Chirico V, Weidemann S, Haese A, Steuber T, Salomon G, Matiu M, Vettorazzi E, Michl U, Budäus L, Tilki D, Thederan I, Pehrke D, Beyer B, Fraune C, Göbel C, Heinrich M, Juhnke M, Möller K, Bawahab AA, Uhlig R, Huland H, Heinzer H, Graefen M, Schlomm T.
Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens.
Eur Urol. 2017 Jan 21. pii: S0302-2838(17)30030-1. doi: 10.1016/j.eururo.2017.01.015. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Sauter G, Steurer S, Clauditz TS, Krech T, Wittmer C, Lutz F, Lennartz M, Janssen T, Hakimi N, Simon R, von Petersdorff-Campen M, Jacobsen F, von Loga K, Wilczak W, Minner S, Tsourlakis MC, Chirico V, Haese A, Heinzer H, Beyer B, Graefen M, Michl U, Salomon G, Steuber T, Budäus LH, Hekeler E, Malsy-Mink J, Kutzera S, Fraune C, Göbel C, Huland H, Schlomm T.
Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens.
Eur Urol. 2016 Apr;69(4):592-8. doi: 10.1016/j.eururo.2015.10.029. Epub 2015 Nov 2.
Comment in: Egevad L et al, Utility of Reporting the Percentage of High-grade Prostate Cancer [Eur Urol. 2016]
Source | Abstract | Full text | Similar articles





ETIOLOGY, PATHOGENESIS AND PATHOLOGY



Sowalsky AG, Kissick HT, Gerrin S, Schaefer R, Xia Z, Russo J, Arredouani MS, Bubley GJ, Sanda MG, Li W, Ye H, Balk SP.
Gleason Score 7 Prostate Cancers Emerge Through Branched Evolution of Clonal Gleason Pattern 3 and 4.
Clin Cancer Res. 2017 Jan 24. pii: clincanres.2414.2016. doi: 10.1158/1078-0432.CCR-16-2414. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Zareba P, Flavin R, Isikbay M, Rider JR, Gerke TA, Finn S, Pettersson A, Giunchi F, Unger RH, Tinianow AM, Andersson SO, Andrén O, Fall K, Fiorentino M, Mucci LA.
Perineural invasion and risk of lethal prostate cancer.
Cancer Epidemiol Biomarkers Prev. 2017 Jan 6. pii: cebp.0237.2016. doi: 10.1158/1055-9965.EPI-16-0237. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





INTEGRATIVE MEDICINE



He Y, Huang H, Farischon C, Li D, Du Z, Zhang K, Zheng X, Goodin S.
Combined effects of atorvastatin and aspirin on growth and apoptosis in human prostate cancer cells.
Oncol Rep. 2017 Feb;37(2):953-960. doi: 10.3892/or.2017.5353. Epub 2017 Jan 4.
Source | Abstract | Full text | Similar articles




Yan J, Wang Y, Jia Y, Liu S, Tian C, Pan W, Liu X, Wang H.
Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer.
Biomed Pharmacother. 2017 Jan 22;88:374-383. doi: 10.1016/j.biopha.2016.12.138. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Yang J, Wang C, Zhang Z, Chen X, Jia Y, Wang B, Kong T.
Curcumin inhibits the survival and metastasis of prostate cancer cells via the Notch-1 signaling pathway.
APMIS. 2017 Feb;125(2):134-140. doi: 10.1111/apm.12650. Epub 2017 Jan 24.
Source | Abstract | Full text | Similar articles





OVERALL MANAGEMENT



Shayegan B.
Prostate cancer, ESMO 2016.
Can Urol Assoc J. 2016 Nov-Dec;10(11-12Suppl6):S231-S234. doi: 10.5489/cuaj.4283.
Source | Abstract | Full text | Similar articles




Sternberg CN, Beltran H.
Prostate cancer in 2016: Improved outcomes and precision medicine come within reach.
Nat Rev Urol. 2017 Feb;14(2):71-72. doi: 10.1038/nrurol.2016.270. Epub 2017 Jan 4.
Source | Abstract | Full text | Similar articles





PROGNOSIS AND OUTCOMES



Williams SB, Huo J, Chamie K, Smaldone MC, Kosarek CD, Fang JE, Ynalvez LM, Kim SP, Hoffman KE, Giordano SH, Chapin BF.
Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data.
Cancer. 2017 Jan 18. doi: 10.1002/cncr.30506. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





TREATMENT



Boulos S, Mazhar D.
The evolving role of chemotherapy in prostate cancer.
Future Oncol. 2017 Jan 18. doi: 10.2217/fon-2016-0464. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Carthon BC.
Clinical Considerations and Challenges in Treating Patients With Oligometastatic Prostate Cancer.
J Oncol Pract. 2017 Jan;13(1):19-20. doi: 10.1200/JOP.2016.018838. Epub 2017 Jan 3.
Source | Abstract | Full text | Similar articles




Clement JM, Sweeney CJ.
Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer.
J Oncol Pract. 2017 Jan;13(1):9-18. doi: 10.1200/JOP.2016.018523. Epub 2017 Jan 3.
Source | Abstract | Full text | Similar articles




Kapoor A, Wu C, Shayegan B, Rybak AP.
Contemporary agents in the management of metastatic castration-resistant prostate cancer.
Can Urol Assoc J. 2016 Nov-Dec;10(11-12):E414-E423. doi: 10.5489/cuaj.4112. Epub 2016 Dec 12.
Source | Abstract | Full text | Similar articles




Tran PT, Antonarakis ES.
Altering the Natural History of Oligometastatic Prostate Cancer With Local Therapies: Reality Versus Illusion.
J Oncol Pract. 2017 Jan;13(1):21-24. doi: 10.1200/JOP.2016.018846. Epub 2017 Jan 3.
Source | Abstract | Full text | Similar articles




Vanneste BG, Van Limbergen EJ, van Lin EN, van Roermund JG, Lambin P.
Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?
Biomed Res Int. 2016;2016:6829875. doi: 10.1155/2016/6829875. Epub 2016 Dec 28.
Source | Abstract | Full text | Similar articles